Search research articles
Contact Us
Filters
Showing results (161-170 of 191) with videos related to
Page
of 20
Sort By:
The Journal of Clinical Endocrinology and Metabolism
|
November 24, 1999
Effect of severe growth hormone (GH) deficiency due to a mutation in the GH-releasing hormone receptor on insulin-like growth factors (IGFs), IGF-binding proteins, and ternary complex formation throughout life
M H Aguiar-Oliveira, M S Gill, E S de A Barretto, et al.
ESMO Open
|
January 28, 2025
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial
F Piscaglia, G Masi, E Martinelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2017
Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey
S Banerjee, R Califano, J Corral, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
Off-label drug use in oncology: integrating molecular and genetic analysis in an academic center's real-world approach
E Cioli, G Suarato, R Napolitano, et al.
Cancer Medicine
|
March 7, 2023
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials
G Martini, D Ciardiello, V Famiglietti, et al.
Pediatric Blood & Cancer
|
August 27, 2014
Low expression of HLA-DRA, HLA-DPA1, and HLA-DPB1 is associated with poor prognosis in pediatric adrenocortical tumors (ACT)
Fabíola A Leite, Regia C P Lira, Paola F Fedatto, et al.
Clinical Endocrinology
|
April 11, 2014
Altered expression of noncanonical Wnt pathway genes in paediatric and adult adrenocortical tumours
Livia M Mermejo, Leticia F Leal, Leandro M Colli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 20, 2014
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial
F Ciardiello, N Normanno, E Maiello, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2016
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX
F Ciardiello, N Normanno, E Martinelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 30, 2024
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF<sup>V600E</sup> wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial
D Ciardiello, L Boscolo Bielo, S Napolitano, et al.
Page
of 20
Search research articles
Search
Showing results (161-170 of 191) with videos related to
Sort By:
Page
of 20
The Journal of Clinical Endocrinology and Metabolism
|
November 24, 1999
Effect of severe growth hormone (GH) deficiency due to a mutation in the GH-releasing hormone receptor on insulin-like growth factors (IGFs), IGF-binding proteins, and ternary complex formation throughout life
M H Aguiar-Oliveira, M S Gill, E S de A Barretto, et al.
ESMO Open
|
January 28, 2025
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial
F Piscaglia, G Masi, E Martinelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2017
Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey
S Banerjee, R Califano, J Corral, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
Off-label drug use in oncology: integrating molecular and genetic analysis in an academic center's real-world approach
E Cioli, G Suarato, R Napolitano, et al.
Cancer Medicine
|
March 7, 2023
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials
G Martini, D Ciardiello, V Famiglietti, et al.
Pediatric Blood & Cancer
|
August 27, 2014
Low expression of HLA-DRA, HLA-DPA1, and HLA-DPB1 is associated with poor prognosis in pediatric adrenocortical tumors (ACT)
Fabíola A Leite, Regia C P Lira, Paola F Fedatto, et al.
Clinical Endocrinology
|
April 11, 2014
Altered expression of noncanonical Wnt pathway genes in paediatric and adult adrenocortical tumours
Livia M Mermejo, Leticia F Leal, Leandro M Colli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 20, 2014
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial
F Ciardiello, N Normanno, E Maiello, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2016
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX
F Ciardiello, N Normanno, E Martinelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 30, 2024
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF<sup>V600E</sup> wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial
D Ciardiello, L Boscolo Bielo, S Napolitano, et al.
Page
of 20